Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count

Abstract

Abstract Lenalidomide is efficient in reducing red blood cell transfusion dependency and markedly lowering platelet counts in MDS/MPN‐RS‐T in the context of major platelet counts.

Keywords

• lenalidomide
• myelodysplastic syndrome
• myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombosis
• myeloproliferative syndrome
• thrombocytosis